Teleflex to sell trio of business lines in deals totalling over $2bn

Teleflex is selling its acute care, interventional urology, and archetypal instrumentality shaper (OEM) businesses successful 2 abstracted deals totalling implicit $2bn arsenic portion of the company’s broader portfolio optimisation strategy.

UK-based Intersurgical is acquiring Teleflex’s acute attraction and interventional urology concern lines for $530m. Meanwhile, Teleflex’s OEM concern is being picked up by backstage equity firms Montagu and Kohlberg successful a carveout woody worthy astir $1.5bn.

Teleflex’s products wrong the segments see intermittent catheters successful urology and airway absorption systems successful acute care, portion its OEM concern is focused connected assembling tools utilized successful areas specified arsenic catheter-based interventions and surgical applications.

Investor sentiment of the latest actions appears positive. Following the announcement of the divestments connected 9 December, Teleflex’s shares connected the New York Stock Exchange (NYSE) roseate by astir 10% to a $131.25 per stock close, up from $119.82 the erstwhile day. Teleflex has a marketplace headdress of $5.8bn.

Both deals are expected to adjacent by H2 2026 pending customary regulatory approvals and different closing conditions.

According to Liam Kelly, Teleflex’s CEO, the selloffs are expected to found the institution arsenic a “more focused” aesculapian technologies leader, with complementary businesses successful vascular access, interventional, and surgical, and a simplified planetary operating exemplary and manufacturing footprint.

“Further, pursuing these transactions, Teleflex volition person accrued flexibility to put successful innovation and vie successful these precedence markets,” Kelly added.

The plans to absorption connected the areas mentioned by Kelly are seemingly borne retired successful Teleflex’s astir caller financials. In the 9 months ended September 28 2025, the lion’s stock of Teleflex’s gross stemmed from the aforementioned concern segments. And for Teleflex’s interventional urology and OEM lines, profits were down by 11% and 13.9%, respectively, versus the aforesaid play of 2024, suggesting a waning focus. What remains unclear, however, is what effect the selloffs volition person connected Teleflex’s antecedently announced intent to divided its concern successful two.

In February 2025, Teleflex announced plans to divided its concern into 2 independently traded entities, with a completion day acceptable for mid-2026. At the time, the institution said that the concern lines that are present being sold disconnected would beryllium grouped nether a caller standalone concern called Teleflex NewCo, with Teleflex’s vascular access, interventional, and surgical businesses grouped nether a caller entity called RemainCo.

Medical Device Network has reached retired to Teleflex for remark connected its outlook for the mooted Teleflex NewCo business.